Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study

P. Emery, C. O. Bingham, G. R. Burmester, V. P. Bykerk, D. E. Furst, X. Mariette, D. Van Der Heijde, R. Van Vollenhoven, C. Arendt, I. Mountian, O. Purcaru, D. Tatla, B. VanLunen, M. E. Weinblatt

Research output: Contribution to journal › Article › peer-review

52 Scopus citations

Fingerprint

Dive into the research topics of 'Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds